Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months
Public ClinicalTrials.gov record NCT00197236. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 Months of Age
Study identification
- NCT ID
- NCT00197236
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 468 participants
Conditions and interventions
Conditions
Interventions
- Havrix™ Biological
- Infanrix™ Biological
- ActHIB™ Biological
Biological
Eligibility (public fields only)
- Age range
- 12 Months to 13 Months
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 10, 2003
- Primary completion
- Dec 2, 2007
- Completion
- Dec 2, 2007
- Last update posted
- Aug 19, 2018
2003 – 2007
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Phoenix | Arizona | 85029 | — |
| GSK Investigational Site | Oakland | California | 94612 | — |
| GSK Investigational Site | San Ramon | California | 94583 | — |
| GSK Investigational Site | Wilmington | Delaware | 19810 | — |
| GSK Investigational Site | Pembroke Pines | Florida | 33027 | — |
| GSK Investigational Site | Martinez | Georgia | 30907 | — |
| GSK Investigational Site | Waterloo | Iowa | 50702 | — |
| GSK Investigational Site | Bossier City | Louisiana | 71111 | — |
| GSK Investigational Site | Long Branch | New Jersey | 07740 | — |
| GSK Investigational Site | Ithaca | New York | 14850 | — |
| GSK Investigational Site | Bismarck | North Dakota | 58501 | — |
| GSK Investigational Site | Youngstown | Ohio | 44501 | — |
| GSK Investigational Site | Bellevue | Pennsylvania | 15202 | — |
| GSK Investigational Site | Hershey | Pennsylvania | 17033 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15241 | — |
| GSK Investigational Site | Charleston | South Carolina | 29425 | — |
| GSK Investigational Site | Beaumont | Texas | 77701 | — |
| GSK Investigational Site | Dallas | Texas | 75235 | — |
| GSK Investigational Site | Danville | Virginia | 24549 | — |
| GSK Investigational Site | Mechanicsville | Virginia | 23111 | — |
| GSK Investigational Site | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00197236, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2018 · Synced Jul 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00197236 live on ClinicalTrials.gov.